Cargando…

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells

We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobardt, Michael, Chatterji, Udayan, Lim, Precious, Gawlik, Katarzyna, Gallay, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009744/
https://www.ncbi.nlm.nih.gov/pubmed/24799968
http://dx.doi.org/10.2174/1874357901408010001
_version_ 1782479795028754432
author Bobardt, Michael
Chatterji, Udayan
Lim, Precious
Gawlik, Katarzyna
Gallay, Philippe
author_facet Bobardt, Michael
Chatterji, Udayan
Lim, Precious
Gawlik, Katarzyna
Gallay, Philippe
author_sort Bobardt, Michael
collection PubMed
description We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the possibility of a relationship between CypA, NS5A and PKR in the IFN response to HCV. HCV-infected cells treated with CypI, DAAs or IFN were analyzed for the expression and activation of various components of the innate response. We found that CypI (cyclosporine A, alisporivir, NIM811 and sanglifehrins), drastically prevented the activation/phosphorylation, but not the expression of IFN-induced PKR in HCV-infected cells. CypI had no effect on the expression or phosphorylation of other components of the innate response such as eiF2, NF-kB, IRF3, IRF9, STAT1 and STAT2, suggesting a specific effect on PKR. No significant activation of IFN-induced PKR was observed in the absence of HCV. Importantly, we found that several classes of DAAs such as NS3/4A protease, NS5B polymerase and NS5A inhibitors also prevented PKR activation. Furthermore, we found that PKR activation by the dsRNA mimic poly I:C cannot be prevented by CypI or DAAs. Our findings suggest that CypI do not have a unique effect on PKR activation, but rather the suppression of HCV replication by any anti-HCV inhibitor, abrogates PKR activation induced by IFN. Moreover, they suggest that the accumulation of dsRNA intermediates allows HCV to exploit the activation of PKR to counteract the IFN response.
format Online
Article
Text
id pubmed-4009744
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-40097442014-05-05 Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells Bobardt, Michael Chatterji, Udayan Lim, Precious Gawlik, Katarzyna Gallay, Philippe Open Virol J Article We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the possibility of a relationship between CypA, NS5A and PKR in the IFN response to HCV. HCV-infected cells treated with CypI, DAAs or IFN were analyzed for the expression and activation of various components of the innate response. We found that CypI (cyclosporine A, alisporivir, NIM811 and sanglifehrins), drastically prevented the activation/phosphorylation, but not the expression of IFN-induced PKR in HCV-infected cells. CypI had no effect on the expression or phosphorylation of other components of the innate response such as eiF2, NF-kB, IRF3, IRF9, STAT1 and STAT2, suggesting a specific effect on PKR. No significant activation of IFN-induced PKR was observed in the absence of HCV. Importantly, we found that several classes of DAAs such as NS3/4A protease, NS5B polymerase and NS5A inhibitors also prevented PKR activation. Furthermore, we found that PKR activation by the dsRNA mimic poly I:C cannot be prevented by CypI or DAAs. Our findings suggest that CypI do not have a unique effect on PKR activation, but rather the suppression of HCV replication by any anti-HCV inhibitor, abrogates PKR activation induced by IFN. Moreover, they suggest that the accumulation of dsRNA intermediates allows HCV to exploit the activation of PKR to counteract the IFN response. Bentham Open 2014-03-07 /pmc/articles/PMC4009744/ /pubmed/24799968 http://dx.doi.org/10.2174/1874357901408010001 Text en © Bobardt et al.; Licensee Bentham Open. http: //creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Bobardt, Michael
Chatterji, Udayan
Lim, Precious
Gawlik, Katarzyna
Gallay, Philippe
Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title_full Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title_fullStr Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title_full_unstemmed Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title_short Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
title_sort both cyclophilin inhibitors and direct-acting antivirals prevent pkr activation in hcv-infected cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009744/
https://www.ncbi.nlm.nih.gov/pubmed/24799968
http://dx.doi.org/10.2174/1874357901408010001
work_keys_str_mv AT bobardtmichael bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells
AT chatterjiudayan bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells
AT limprecious bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells
AT gawlikkatarzyna bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells
AT gallayphilippe bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells